Bayer Ends Phase 2 Trial of Riociguat in PH Patients with Idiopathic Interstitial Pneumonias
News, Pulmonary Hypertension
Bayer has stopped a Phase 2 clinical trial (NCT02138825) evaluating riociguat (Adempas) in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) on the recommendation of the study’s Data Monitoring Committee (DMC). The committee — sometimes ... Read more